A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience (Q46938228)

26 December 2017

title

A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience (English)

1 reference

26 December 2017

main subject

metastatic breast cancer

1 reference

Ryan H Engel

1

1 reference

26 December 2017

Jennifer A Brown

2

1 reference

26 December 2017

Jamie H Von Roenn

3

1 reference

26 December 2017

Ruth M O'Regan

4

1 reference

26 December 2017

Raymond Bergan

5

1 reference

26 December 2017

Sunil Badve

6

1 reference

26 December 2017

Alfred Rademaker

7

1 reference

26 December 2017

William J Gradishar

8

1 reference

26 December 2017

publication date

18 October 2007

1 reference

26 December 2017

published in

Cancer Investigation

1 reference

26 December 2017

volume

25

1 reference

26 December 2017

page(s)

733-737

1 reference

26 December 2017

issue

8

1 reference

26 December 2017

The ubiquitin-proteasome pathway and proteasome inhibitors

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

Proteasome: an emerging target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

How proteolysis drives the cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

The proteasome: a novel target for cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

The role of the ubiquitin-proteasome pathway in apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to Bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

Benign lesions in cancer patients: Case 1. Sarcoidosis after chemoradiation for head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701506573

10.1080/07357900701506573

21 January 2018

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

17952740

1 reference

26 December 2017